Payment overview · 2025
General Payments
$632.99
29 reported records · 8 companies
Healthcare provider profile · identity verified
Anna Marinovich, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · BROOKLYN, NY · NPI 1114987237
Verified facts
What the public records show
CMS Open Payments records show Anna Marinovich, M.D. received $632.99 in general payments during 2025 across 29 reported records.
AstraZeneca Pharmaceuticals LP accounted for 45.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Farxiga, Linzess, Ozempic, Prolia, Rybelsus, Trelegy Ellipta, Xifaxan.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 134 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 129 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 142 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Nexium by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Rybelsus by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULANCE as an associated drug or biological on 2652 records involving 1501 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Trulance by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIFAXAN as an associated drug or biological on 101901 records involving 33018 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Xifaxan by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $289.36 | 45.7% | 12 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $69.78 | 11.0% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $67.68 | 10.7% | 4 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $60.38 | 9.5% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $53.27 | 8.4% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $48.85 | 7.7% | 2 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $22.39 | 3.5% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $21.28 | 3.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $632.99 | 29 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $165.26 | 6 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $124.10 | 6 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $69.78 | 3 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $67.68 | 4 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $60.38 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $48.85 | 2 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $34.37 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $31.05 | 2 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $31.05 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $24.58 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $22.39 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $22.22 | 1 | 2025 |
Source payment records
|
|||||
| LAGEVRIO Normalized: lagevrio |
Drug | Merck Sharp & Dohme LLC | $21.28 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 134 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 142 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 129 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| PROLIA prolia |
2025 | Prolia | 2024 | 52 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 42 | exact normalized | Medicare Part D |
| XIFAXAN xifaxan |
2025 | Xifaxan | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
134 | 28 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
129 | 26 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
56 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
52 | 29 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
142 | 27 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | NEXIUM open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180 |
Nexium · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
42 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | TRULANCE open payments reported associated product |
CMS Open Payments — General Payments 2652 supporting records · 1501 recipient NPIs · example record 1231775445 |
Trulance · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | XIFAXAN open payments reported associated product |
CMS Open Payments — General Payments 101901 supporting records · 33018 recipient NPIs · example record 1231775337 |
Xifaxan · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Losartan Potassium | Losartan Potassium | 460 | 87 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 418 | 79 |
| Atorvastatin Calcium | Atorvastatin Calcium | 400 | 80 |
| Metoprolol Succinate | Metoprolol Succinate | 304 | 62 |
| Allopurinol | Allopurinol | 295 | 45 |
| Diclofenac Sodium | Diclofenac Sodium | 275 | 59 |
| Metformin Hcl | Metformin Hcl | 266 | 48 |
| Tamsulosin Hcl | Tamsulosin Hcl | 248 | 45 |
| Furosemide | Furosemide | 222 | 51 |
| Jardiance | Empagliflozin | 217 | 28 |
| Amlodipine Besylate | Amlodipine Besylate | 208 | 49 |
| Nebivolol Hcl | Nebivolol Hcl | 161 | 26 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 154 | 36 |
| Clopidogrel | Clopidogrel Bisulfate | 152 | 31 |
| Farxiga | Dapagliflozin Propanediol | 142 | 27 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 136 | 33 |
| Eliquis | Apixaban | 135 | 25 |
| Creon | Lipase/Protease/Amylase | 134 | 28 |
| Linzess | Linaclotide | 129 | 26 |
| Omeprazole | Omeprazole | 128 | 35 |
| Simvastatin | Simvastatin | 126 | 24 |
| Carvedilol | Carvedilol | 122 | 23 |
| Levothyroxine Sodium | Levothyroxine Sodium | 121 | 19 |
| Entresto | Sacubitril/Valsartan | 117 | 14 |
| Metoprolol Tartrate | Metoprolol Tartrate | 117 | 21 |
| Lisinopril | Lisinopril | 111 | 19 |
| Memantine Hcl | Memantine Hcl | 105 | 18 |
| Finasteride | Finasteride | 104 | 18 |
| Chlorthalidone | Chlorthalidone | 101 | 35 |
| Famotidine | Famotidine | 96 | 30 |
| Pravastatin Sodium | Pravastatin Sodium | 96 | 15 |
| Fluticasone Propionate | Fluticasone Propionate | 90 | 55 |
| Ammonium Lactate | Ammonium Lactate | 86 | 18 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 85 | 25 |
| Valacyclovir | Valacyclovir Hcl | 84 | 29 |
| Zenpep | Lipase/Protease/Amylase | 83 | 23 |
| Escitalopram Oxalate | Escitalopram Oxalate | 78 | 16 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 76 | 13 |
| Alendronate Sodium | Alendronate Sodium | 75 | 14 |
| Pantoprazole Sodium | Pantoprazole Sodium | 75 | 17 |
| Meloxicam | Meloxicam | 74 | 24 |
| Hydralazine Hcl | Hydralazine Hcl | 73 | 14 |
| Xarelto | Rivaroxaban | 71 | suppressed |
| Cilostazol | Cilostazol | 69 | 12 |
| Azithromycin | Azithromycin | 68 | 57 |
| Glipizide Er | Glipizide | 65 | 11 |
| Ranolazine Er | Ranolazine | 65 | suppressed |
| Nifedipine Er | Nifedipine | 64 | suppressed |
| Januvia | Sitagliptin Phosphate | 63 | 13 |
| Lactulose | Lactulose | 61 | 28 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 59 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 58 | 12 |
| Synthroid | Levothyroxine Sodium | 56 | suppressed |
| Bystolic | Nebivolol Hcl | 55 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 54 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 54 | suppressed |
| Prolia | Denosumab | 52 | 29 |
| Spironolactone | Spironolactone | 52 | 14 |
| Edarbi | Azilsartan Medoxomil | 48 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 47 | suppressed |
| Diclofenac Epolamine | Diclofenac Epolamine | 47 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 46 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 45 | suppressed |
| Glimepiride | Glimepiride | 45 | suppressed |
| Prednisone | Prednisone | 45 | 31 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 42 | 11 |
| Trulance | Plecanatide | 42 | suppressed |
| Naproxen | Naproxen | 41 | 19 |
| Atenolol | Atenolol | 39 | suppressed |
| Ibuprofen | Ibuprofen | 39 | 24 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 38 | suppressed |
| Valsartan | Valsartan | 38 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 36 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 35 | 15 |
| Irbesartan | Irbesartan | 35 | suppressed |
| Nitroglycerin | Nitroglycerin | 34 | 21 |
| Torsemide | Torsemide | 34 | 13 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 33 | suppressed |
| Vascepa | Icosapent Ethyl | 32 | 12 |
| Naproxen-Esomeprazole Mag | Naproxen/Esomeprazole Mag | 31 | suppressed |
| Ramipril | Ramipril | 30 | suppressed |
| Rybelsus | Semaglutide | 30 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 29 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 29 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 29 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 28 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 28 | suppressed |
| Dexilant | Dexlansoprazole | 27 | suppressed |
| Lidocaine | Lidocaine | 27 | suppressed |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 27 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 27 | suppressed |
| Tradjenta | Linagliptin | 27 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 26 | suppressed |
| Ozempic | Semaglutide | 26 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 25 | suppressed |
| Clonazepam | Clonazepam | 24 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 24 | suppressed |
| Evenity (2 Syringes) | Romosozumab-Aqqg | 24 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 23 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 23 | suppressed |
| Metformin Er Gastric | Metformin Hcl | 23 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 23 | 12 |
| Ciclopirox | Ciclopirox | 22 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 22 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 21 | suppressed |
| Colchicine | Colchicine | 21 | 16 |
| Telmisartan | Telmisartan | 21 | suppressed |
| Xifaxan | Rifaximin | 21 | suppressed |
| Methimazole | Methimazole | 20 | suppressed |
| Terconazole | Terconazole | 20 | 11 |
| Icosapent Ethyl | Icosapent Ethyl | 19 | suppressed |
| Myrbetriq | Mirabegron | 19 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 19 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 18 | suppressed |
| Lansoprazole | Lansoprazole | 18 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 17 | 15 |
| Gabapentin | Gabapentin | 17 | suppressed |
| Mounjaro | Tirzepatide | 17 | suppressed |
| Mupirocin | Mupirocin | 17 | 11 |
| Warfarin Sodium | Warfarin Sodium | 17 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Dutasteride | Dutasteride | 16 | suppressed |
| Ursodiol | Ursodiol | 16 | suppressed |
| Crestor | Rosuvastatin Calcium | 15 | suppressed |
| Diclofenac Sodium Er | Diclofenac Sodium | 15 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 15 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 15 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 14 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 14 | suppressed |
| Clotrimazole | Clotrimazole | 14 | 11 |
| Glipizide | Glipizide | 14 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 14 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 13 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 13 | suppressed |
| Eletriptan Hbr | Eletriptan Hydrobromide | 13 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 13 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 13 | suppressed |
| Trulicity | Dulaglutide | 13 | suppressed |
| Zolmitriptan | Zolmitriptan | 13 | suppressed |
| Lunesta | Eszopiclone | 12 | suppressed |
| Nexium | Esomeprazole Magnesium | 12 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 12 | suppressed |
| Benicar Hct | Olmesartan/Hydrochlorothiazide | 11 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 11 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 11 | suppressed |
| Eplerenone | Eplerenone | 11 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 11 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 11 | suppressed |
| Ztlido | Lidocaine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $632.99 · 29 records | AstraZeneca Pharmaceuticals LP | BREZTRI, CREON, EVENITY, FARXIGA, LAGEVRIO, LINZESS, Ozempic, PROLIA, REPATHA, Rybelsus, TRELEGY ELLIPTA, XIFAXAN, ZORYVE | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error